Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma

Figure 1 Representative case of a 69-year-old man with unresectable hepatocellular carcinoma treated with lenvatinib (12 mg/d). A: Contrast-enhanced ultrasound (CEUS) imaging in the arterial phase at Day 0 and time-intensity curve (TIC) analysis. The region of interest was established within the demarcation margins of the target tumor. B: CEUS imaging at Day 7 and TIC analysis. The slope became gentle, and indicated a delay in TTP and a decrease in the area under the curve. C: Computed tomography (CT) image at Day 0. D: CT image at 8 wk. Therapeutic response was evaluated as partial response using the modified Response Evaluation Criteria in Solid Tumors. TTP: Time to peak; AUC: Area under the curve.